What Are Precursor Blood Conditions and How Are They Treated?

Precursor conditions are early phases of blood diseases that may develop into cancers such as lymphoma, leukemia, Waldenström’s macroglobulinemia, and multiple myeloma. Most people do not experience symptoms, and since doctors rarely screen for precursor conditions, they are often diagnosed after routine blood tests.

Cancer research, multiple myeloma

Irene Ghobrial, MD, is working to understand why some precursor conditions develop into cancer.

“Many diagnoses are purely incidental,” says Irene Ghobrial, MD, co-principal investigator at the Center for Prevention of Progression of Blood Cancers (CPOP) at Dana-Farber Cancer Institute and medical oncologist in the Jerome Lipper Multiple Myeloma Center at Dana-Farber/Brigham and Women’s Cancer Center. Patients with a precursor condition are often told to “watch and wait.” In other words, the condition is monitored and treatment only begins if it develops into cancer. Not every person diagnosed with a precursor condition will be diagnosed with a blood cancer, but many cases of blood cancer do develop from precursor conditions.

Precursor blood conditions include:

  • Early Myelodysplastic Syndrome (MDS), a condition in which the bone marrow does not produce enough healthy blood cells. In advanced stages, MDS may progress to acute myeloid leukemia (AML).
  • Monoclonal Gammopathy of Undetermined Significance (MGUS), a condition in which there are abnormal plasma cells in the bone marrow. These cells produce monoclonal proteins, which routine blood and urine tests sometimes detect. In some cases, MGUS progresses into multiple myeloma. About 3 percent of adults over age 50 have MGUS, according to Ghobrial. Multiple myeloma is almost always preceded by MGUS, although not every case of MGUS will evolve into multiple myeloma, she explains.
  • Smoldering multiple myeloma, a condition in which there are abnormal plasma cells in the bone marrow that produce monoclonal proteins or free light-chains, smaller units of the immunoglobulin produced by plasma cells.
  • Smoldering Waldenström’s macroglobulinemia, a condition in which there are abnormal lymphocytes and plasma cells in the bone marrow that secrete monocolonal proteins of IgM type. This condition may progress to Waldenström’s macroglobulinemia.

 

Researchers at the CPOP, led by Robert Soiffer, MDDavid Steensma, MDBenjamin Ebert, MD, PhD; and Ghobrial, seek to understand why some patients with precursor conditions develop cancer and others do not, with the goal of some day developing treatments that can delay or stop the progression of precursor conditions, and eventually eradicate them. The research is driven by the center’s PCROWD study, which collects, processes, and stores tissue samples from people with precursor conditions from across the United States.

Comments Sort By Newest

Leave a Reply

Your email address will not be published. Required fields are marked *

Blue Captcha Image
Refresh

*

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
From young patient to college student, Hannah has been all smiles with the support of her family and caregivers:… https://t.co/oSxMljQOyZ
Dana-Farber @danafarber
Congratulations to Scott Armstrong, MD, PhD, and Alan D’Andrea, MD, on their election to @theNAMedicine.… https://t.co/Ff9JYnG3uB
Dana-Farber @danafarber
Get your squad involved w/ #CheerforDanaFarber & earn @PatsCheer prizes. Learn more: https://t.co/xPG55AS3TAhttps://t.co/U9lJdKSxSS

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.